ReviewJournal of neurology2021
Axonal variants of Guillain-Barré syndrome: an update.
Review in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Association between Guillain-Barré syndrome and SARS-CoV-2 virus infection, including the impact of COVID-19 vaccination in the context of the development and general clinical characteristics of the disease.Journal of neurovirology · 2025Pooled it
- Triggers of Guillain-Barré Syndrome:International journal of molecular sciences · 2022Pooled it
- Guillain-Barré syndrome following intracranial hemorrhage: a systematic review of case reports.Frontiers in neurologyPooled it
- Augmented reality assisted physiotherapy rehabilitation in early phase of guillain barre syndrome (AIDP)-a case report.BMC neurology · 2026Article
- Brentuximab-Induced Peripheral Neuropathy in the Setting of Radiation-Induced Brachial Plexopathy.Cureus · 2026Article
- Unilateral facial palsy with hemiplegia and positive anti-GT1a antibody: a case report and literature review.Frontiers in immunology · 2026Review
- Article
- Pinosylvin: A Multifunctional Stilbenoid with Antimicrobial, Antioxidant, and Anti-Inflammatory Potential.Current issues in molecular biology · 2025Review
- Numbness on the Medical Take: An Atypical Presentation of Guillain-Barre Syndrome With Unilateral Paraesthesia and Rapid Progression to Bulbar Palsy: A Case Report.Clinical case reports · 2025Article
- Case Report: Guillain-Barré syndrome temporally associated with levofloxacin exposure and improvement following efgartigimod treatment.Frontiers in immunology · 2025Article
- Lactobacillus rhamnosus ameliorates experimental autoimmune neuritis via modulation of gut microbiota and metabolites.Heliyon · 2024Article
- [Epidemiological and clinical aspects of Guilain-Barré syndrome, 2012-2022].Revista medica del Instituto Mexicano del Seguro Social · 2024Observational
- Article
- A Rare Presentation of Guillain-Barré Syndrome With Associated Horner Syndrome: A Case Report.Cureus · 2024Article
- An updated review on Guillain-Barré syndrome: Challenges in infection prevention and control in low- and middle-income countries.SAGE open medicine · 2024Review
- A rare association of Guillain-Barré syndrome/Miller-Fisher syndrome overlap syndrome and Herpes Simplex Virus Type 1 infection: trigger or exacerbating factor?Therapeutic advances in neurological disorders · 2024Article
- Autoimmune disease: a view of epigenetics and therapeutic targeting.Frontiers in immunology · 2024Review
- Transforming medicine: artificial intelligence integration in the peripheral nervous system.Frontiers in neurology · 2024Review
- Early electrophysiological study variants and their relationship with clinical presentation and outcomes of patients with Guillain-Barré syndrome.Scientific reports · 2023Article
- Stealth invaders: unraveling the mystery of neurotropic viruses and their elusive presence in cerebrospinal fluid - a comprehensive review.Annals of medicine and surgery (2012) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Axonal variants of Guillain-Barré syndrome (GBS) mainly include acute motor axonal neuropathy, acute motor and sensory axonal neuropathy, and pharyngeal-cervical-brachial weakness. Molecular mimicry of human gangliosides by a pathogen's lipooligosaccharides is a well-established mechanism for Campylobacter jejuni-associated GBS. New triggers of the axonal variants of GBS (axonal GBS), such as Zika virus, hepatitis viruses, intravenous administration of ganglioside, vaccination, and surgery, are being identified. However, the pathogenetic mechanisms of axonal GBS related to antecedent bacterial or viral infections other than Campylobacter jejuni remain unknown. Currently, autoantibody classification and serial electrophysiology are cardinal approaches to differentiate axonal GBS from the prototype of GBS, acute inflammatory demyelinating polyneuropathy. Newly developed technologies, including metabolite analysis, peripheral nerve ultrasound, and feature selection via artificial intelligence are facilitating more accurate diagnosis of axonal GBS. Nevertheless, some key issues, such as genetic susceptibilities, remain unanswered and moreover, current therapies bear limitations. Although several therapies have shown considerable benefits to experimental animals, randomized controlled trials are still needed to validate their efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.